Table 2.
Top 10 Genes, Comparing T2DM Cases with Controls
| Thiazide diuretic Study† | ||||
|
| ||||
| Gene | Ratio of Means | % FC | P-value, unadjusted | FDR/Q-value |
| CCL14 | 0.938 | -6% | 1.22E-6 | 0.026 |
| MIR1226 | 1.108 | 11% | 3.45E-5 | 0.363 |
| OR2A7 | 1.053 | 5% | 0.0002 | 0.837 |
| TOP2A | 1.113 | 11% | 0.0002 | 0.837 |
| EXT2 | 0.949 | -5% | 0.0003 | 0.870 |
|
| ||||
|---|---|---|---|---|
| Statin Study‡ | ||||
|
| ||||
| Gene | Fold change | % FC | P-value, unadjusted | FDR/Q-value |
|
| ||||
| ZNF532 | 1.150 | 15% | 4.47E-6 | 0.058 |
| CXORF21 | 1.105 | 11% | 7.02E-6 | 0.058 |
| ZNHIT3 | 1.185 | 19% | 1.73E-5 | 0.096 |
| EBAG9 | 1.098 | 10% | 9.34E-5 | 0.332 |
| PHF10 | 0.886 | -11% | 0.0001 | 0.332 |
†
Analyses among thiazide users: adjusted for age; sex; BMI; chip; prior AF, MI, VTE, stroke; time taking thiazides; follow-up time; use of any other hypertension medication; 5 SVs.
‡
Analyses among statin users: adjusted for age; sex; BMI; chip version; use of diuretics; use of any other hypertensive medications; 3 SVs.